Dr. John M. Delgaudio, MD

Dr. Delgaudio practices at Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University.

Dr. Delgaudio's NPI, 1104937861, was assigned on August 31, 2006. Dr. Delgaudio graduated from Jefferson Medical College of Thomas Jefferson University in 1989. Dr. Delgaudio holds Georgia license 39772.

Dr. Delgaudio's primary practice is Emory University Hospital Midtown, at 550 Peachtree Street, NE, Atlanta, GA 30308 in Fulton County. The practice phone is (404) 686-2450.

Dr. Delgaudio's primary practice is Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University. Dr. Delgaudio is also affiliated with Emory University Hospital. The medical group on file is Emory Clinic. Dmand AI also links Dr. Delgaudio to 2 more group practices and clinics, 1 clinical lab and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Delgaudio practices, 5 sites in all. Vendor and product names are available with a free account.

Otolaryngic allergy is Dr. Delgaudio's primary specialty in the NPI Registry, under taxonomy code 207YX0602X. Dr. Delgaudio is licensed in Georgia.

CMS data shows 379 Medicare services from Dr. Delgaudio across 9 procedure codes in 2024, for 127 Medicare patients. Medicare paid $60,546 for them.

CMS counts 127 Medicare patients who saw Dr. Delgaudio in 2024. The largest group is 65 to 74, with 64 patients. 74% of them have high cholesterol, and 71% have high blood pressure. Their average risk score is 1.19, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Delgaudio's median patient age at 57, with 52% women.

In 2024, Dr. Delgaudio wrote 49 Medicare Part D claims for 30 patients. 98% of them were for generic drugs. CMS names the drug for 15 of them, across 1 drug with 11 or more claims each, at $173 in total drug cost. In 2023, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Delgaudio for performance year 2024, reported through an alternative payment model (APM). Dr. Delgaudio accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 76 papers to Dr. Delgaudio, published from 2011 to 2024. 2019 was the busiest year, with 8. The most frequent topics are Sinusitis, Endoscopy and Rhinitis. Dr. Delgaudio has published most often in Int Forum Allergy Rhinol. Dr. Delgaudio's most frequent co-authors are Sarah K. Wise, MD, Zara Marzban Patel, MD and Lauren Tashima Roland, MD.

Dmand AI links Dr. Delgaudio to 2 clinical trials. Conditions studied include Nasal Obstruction and Airway Obstruction. Spirox, Inc. sponsors the most, 2. Open Payments lists research payments to Dr. Delgaudio that name 2 trials.

CMS Open Payments shows 119 general payments to Dr. Delgaudio from 19 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 59% of the total. Medtronic USA, Inc. paid the most, $39,534. It also lists 4 research payments totaling $37,050 in 2017, naming 2 clinical trials.

Dr. Delgaudio graduated from Jefferson Medical College of Thomas Jefferson University in 1989.